Real-world evidence (RWE) supports the efficacy of Ibrance plus letrozole in breast cancer
21 April 2022
- Data published in Breast Cancer Research showed real-world efficacy of palbociclib (Ibrance) in combination with letrozole in women with hormone receptor–positive, HER2-negative metastatic breast cancer versus letrozole alone
- These findings which showed extended overall and progression-free survival (PFS) benefit with the combination represents the first comprehensive comparative effectiveness analysis of outcomes for a CDK4/6 inhibitor in clinical practice
- “Real-world evidence is woven into the fabric of how we innovate and advance care for patients with breast cancer, supporting our randomized clinical trials
- With more than 6 years of patient experience, a positive benefit-risk profile, strong clinical data, and robust real-world data, the totality of evidence solidifies the role of palbociclib plus endocrine therapy as a treatment for patients with metastatic breast cancer.”
Chris Boshoff, MD, PhD, Chief Development Officer, Oncology, Pfizer Global Product DevelopmentClick here to learn more.